Tecnisa (TCSA3) Q4 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2024 earnings summary
14 Oct, 2026Executive summary
2024 launches totaled R$1.621bn PSV, achieving 95% of Jardim das Perdizes launch guidance; adjusted cash generation was R$95m.
Net sales at 100% reached R$949m, up 49% YoY; attributable net sales were R$609m, up 16%.
FY24 consolidated net loss was R$151.053m, versus R$55.267m in FY23.
Financial highlights
Net revenue was R$696m in FY24, up 39% YoY; consolidated net operating revenue was R$455.222m, versus R$423.414m in FY23.
Consolidated cost of sales and services was R$493.510m, producing a gross loss of R$38.288m, versus gross profit of R$20.867m in FY23.
Adjusted gross profit including equity-method projects was R$118m for FY24 and R$42m in 4Q24; FY24 rose 11% YoY, while 4Q24 rose 503%.
Adjusted EBITDA was a R$37m loss in FY24 versus R$27m profit in FY23; reported EBITDA loss was R$98m versus R$24m.
G&A expenses fell 7% to R$55m and selling expenses fell 17% to R$23m in FY24.
Outlook and guidance
Jardim das Perdizes launch targets are R$1.5bn PSV in 2025 and R$2.1bn in 2026; the 2024–2026 plan totals R$5.3bn PSV, including R$2.8bn attributable share.
2025 deliveries across six projects were expected to generate cash; 2025 receivables were R$473m against R$237m of debt maturities.
The 2025 delivery schedule included Highlights Dr. Nelson Moretti, whose occupancy permit was issued in January 2025; the project has R$154m PSV.
Latest events from Tecnisa
- Revenue rose 194% YoY, with a 29.6% adjusted margin and a third straight profitable quarter.TCSA3
Q1 2023 - Revenue rose 151% as profitability continued; a R$4.31bn landbank supports launches.TCSA3
Q2 2023 - Gross sales rose, but an R$8.101 million Q3 loss and negative operating cash flow weighed on liquidity.TCSA3
Q3 2023 - CEPACs unlock R$5.3 billion in launches as FY2023 ends with a R$55.3 million net loss.TCSA3
Q4 2023 - Sales rose, but Q1 ended with a R$20.7m loss and elevated debt.TCSA3
Q1 2024 - Sales and backlog profit grew, while losses and high leverage weighed on results.TCSA3
Q2 2024 - Sales advanced, but cancellations, weak margins and Belaterra litigation weighed on results.TCSA3
Q3 2024 - Cash generation and backlog profit improved, despite weaker revenue and ongoing financial risks.TCSA3
Q1 2025 - A conditional R$260.9 million stake sale may ease debt amid a R$20.7 million net loss.TCSA3
Q1 2026